KR20240134900A - 자가항체 매개 질환 환자를 치료하기 위한 방법 - Google Patents

자가항체 매개 질환 환자를 치료하기 위한 방법 Download PDF

Info

Publication number
KR20240134900A
KR20240134900A KR1020247023836A KR20247023836A KR20240134900A KR 20240134900 A KR20240134900 A KR 20240134900A KR 1020247023836 A KR1020247023836 A KR 1020247023836A KR 20247023836 A KR20247023836 A KR 20247023836A KR 20240134900 A KR20240134900 A KR 20240134900A
Authority
KR
South Korea
Prior art keywords
subject
fcrn antagonist
cells
autoantibody
frequency
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247023836A
Other languages
English (en)
Korean (ko)
Inventor
페터르 페르헤선
막달레나 십스
로베르트 폴만
미하엘 헤르틀
파스깔 졸리
세바스띠앙 깔보
모드 마오-바양
Original Assignee
아르젠엑스 비브이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아르젠엑스 비브이 filed Critical 아르젠엑스 비브이
Publication of KR20240134900A publication Critical patent/KR20240134900A/ko
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N2015/1006—Investigating individual particles for cytology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N2015/1486—Counting the particles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020247023836A 2022-01-17 2023-01-17 자가항체 매개 질환 환자를 치료하기 위한 방법 Pending KR20240134900A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263266852P 2022-01-17 2022-01-17
US63/266,852 2022-01-17
PCT/EP2023/050980 WO2023135321A1 (en) 2022-01-17 2023-01-17 Methods for treating patients with an autoantibody-mediated disease

Publications (1)

Publication Number Publication Date
KR20240134900A true KR20240134900A (ko) 2024-09-10

Family

ID=85036487

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247023836A Pending KR20240134900A (ko) 2022-01-17 2023-01-17 자가항체 매개 질환 환자를 치료하기 위한 방법

Country Status (12)

Country Link
US (1) US20240369467A1 (https=)
EP (1) EP4466539A1 (https=)
JP (1) JP2025504815A (https=)
KR (1) KR20240134900A (https=)
CN (1) CN118556187A (https=)
AR (1) AR128284A1 (https=)
AU (1) AU2023207461A1 (https=)
CA (1) CA3241453A1 (https=)
IL (1) IL314322A (https=)
MX (1) MX2024007806A (https=)
TW (1) TW202333791A (https=)
WO (1) WO2023135321A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3081144A1 (en) 2017-12-08 2019-06-13 Argenx Bvba Use of fcrn antagonists for treatment of generalized myasthenia gravis
US12202900B2 (en) 2018-06-08 2025-01-21 argenx BV Compositions and methods for treating immune thrombocytopenia
JP2023509195A (ja) 2020-01-08 2023-03-07 アルジェニクス ビーブイ 天疱瘡症を治療する方法
CN119698429A (zh) 2022-06-15 2025-03-25 阿根思有限公司 Fcrn结合分子及使用方法
TW202421195A (zh) * 2022-11-07 2024-06-01 比利時商阿根思公司 使用ｆｃｒｎ拮抗劑治療狼瘡性腎炎之方法
WO2025093717A1 (en) * 2023-10-31 2025-05-08 Immunovant Sciences Gmbh Methods of improving anti-fcrn therapies
WO2025202714A1 (en) * 2024-03-26 2025-10-02 argenx BV Methods for treating primary sjogren's syndrome using fcrn antagonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2158318A2 (en) 2007-05-14 2010-03-03 Biogen Idec MA, Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
KR102904658B1 (ko) * 2017-12-13 2025-12-29 모멘타 파머슈티컬스 인코포레이티드 FcRn 항체 및 이의 사용 방법
JP2023509195A (ja) * 2020-01-08 2023-03-07 アルジェニクス ビーブイ 天疱瘡症を治療する方法

Also Published As

Publication number Publication date
WO2023135321A1 (en) 2023-07-20
MX2024007806A (es) 2024-07-04
AR128284A1 (es) 2024-04-10
AU2023207461A1 (en) 2024-07-11
EP4466539A1 (en) 2024-11-27
CN118556187A (zh) 2024-08-27
JP2025504815A (ja) 2025-02-19
CA3241453A1 (en) 2023-07-20
TW202333791A (zh) 2023-09-01
US20240369467A1 (en) 2024-11-07
IL314322A (en) 2024-09-01

Similar Documents

Publication Publication Date Title
KR20240134900A (ko) 자가항체 매개 질환 환자를 치료하기 위한 방법
US11667905B2 (en) Cysteine protease
Yamamoto et al. Value of serum IgG4 in the diagnosis of IgG4-related disease and in differentiation from rheumatic diseases and other diseases
Maho-Vaillant et al. FcRn antagonism leads to a decrease of desmoglein-specific B cells: secondary analysis of a phase 2 study of efgartigimod in pemphigus vulgaris and pemphigus foliaceus
Thiel et al. Genetic CD21 deficiency is associated with hypogammaglobulinemia
Baker et al. Immunogenicity of protein therapeutics: the key causes, consequences and challenges
KR101832510B1 (ko) 치료 항-ｉｇｅ 항체에 대해 특이적인 항체를 검출하기 위한 검정 및 아나필락시스에서의 이의 용도
EP3256579B1 (en) Cysteine protease
JP6305919B2 (ja) Ｍｃａｍアンタゴニスト及び治療の方法
JP2021050235A (ja) 免疫療法における改変Ｆｃ断片の使用
KR20040105740A (ko) 염증 치료제의 투여 방법
US11999798B2 (en) Anti-factor IX padua antibodies
Zhang et al. A recombinant human IgG1 Fc multimer designed to mimic the active fraction of IVIG in autoimmunity
CN1729398A (zh) 心血管疾病的检测
CN113574071A (zh) 用于治疗自身抗体介导的自身免疫疾病的抗-cd38抗体及其药物组合物
KR20250134146A (ko) 소아 장애를 치료하는 방법
HK40109266A (zh) 用於治疗患有自身抗体介导的疾病的患者的方法
US20250297324A1 (en) Biomarkers of IL7R Modulator Activity
US20220308056A1 (en) Biomarker for assessing the risk of developing acute covid-19 and post-acute covid-19
JP7550142B2 (ja) 関節リウマチ治療のためのバイオマーカー
Gonzalez et al. Autoimmune syndrome after induction of neonatal tolerance to I‐E antigens
WO2022168861A1 (ja) 自己免疫疾患治療剤
WO2015150815A1 (en) Methods and materials relating to auto-immune disease
Fernández et al. Immunogenicity in protein and peptide basedtherapeutics: An overview
CN117280213A (zh) 生物标志物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000